HELSINKI, Finland, June 4, 2014-Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Dr Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer (CMO).
Dr Jaderberg is a pharmaceutical physician with more than 25 years’ experience in various R&D functions, including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management. His therapeutic area expertise includes immunology, oncology and infectious diseases.
Dr Jaderberg has experience of all phases of clinical research, including clinical pharmacology, dose finding, registration, post launch product differentiation and surveillance. His immunotherapy expertise includes Yervoy (ipilimumab), Enbrel (etanercept), Torisel (temsirolimus), Orencia (abatacept), Rapamune (sirolimus) and Nulojix (belatacept).
“We are very happy to announce the recruitment of Magnus to our team. He will bring strategic expertise and knowledge to our prioritized research and clinical development of novel cancer immune therapies”, commented Frans Wuite, M.D., President and CEO of Oncos Therapeutics.
Dr Jaderberg studied medicine at the Karolinska Institute, Stockholm, Sweden, and is registered to practise medicine in Sweden and the UK. He was honorary lecturer in drug development at King’s College, London between 2003 and 2009, and he is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.
Prior to joining Oncos Therapeutics, Dr Jaderberg held senior position roles at national, European and global level at GlaxoSmithKline, Pharmacia, Wyeth and Bristol Myers Squibb (BMS). His most recent position was as Chief Medical Officer, at BMS Europe.
Dr Jaderberg joined Oncos Therapeutics on June 1, 2014.
For more information, please contact:
Antti Vuolanto, COO and co-founder
Oncos Therapeutics Ltd.
About Oncos Therapeutics
Oncos Therapeutics Ltd is a privately funded clinical-stage biotechnology company focused on the development and commercialization of targeted cancer immunotherapy products that induce a tailored immune response targeted against each patient’s unique cancer cells. In addition to its lead product, ONCOS-102, Oncos has generated a pipeline of clinical candidates using its adenovirus-based cancer immunotherapeutics platform. The company’s lead investor is HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe. Oncos, founded in 2009, is headquartered in Helsinki, Finland and has an office in Switzerland. For more information about Oncos, please visit www.oncos.com.